Open | $0.139 |
Close | $0.141 |
Volume / Avg. | 1.807M / 2.184M |
Day Range | 0.134 - 0.142 |
52 Wk Range | 0.125 - 47.100 |
Market Cap | $2.716M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 25 |
Short Interest | 3.54% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Biolase (NASDAQ: BIOL) through any online brokerage.
Other companies in Biolase’s space includes: NeuroMetrix (NASDAQ:NURO), Acutus Medical (NASDAQ:AFIB), Nexalin Technology (NASDAQ:NXL), Bluejay Diagnostics (NASDAQ:BJDX) and Venus Concept (NASDAQ:VERO).
The latest price target for Biolase (NASDAQ: BIOL) was reported by Lake Street on Wednesday, May 31, 2023. The analyst firm set a price target for 0.40 expecting BIOL to rise to within 12 months (a possible 182.69% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Biolase (NASDAQ: BIOL) is $0.1415 last updated March 18, 2024 at 6:31 PM EDT.
A quarterly cash dividend of $0.01 per share of Class A Common Stock. The quarterly cash dividend was payable on June 28, 2013 to stockholders of record on June 12, 2013.
Biolase’s Q1 earnings are confirmed for Thursday, May 9, 2024.
There is no upcoming split for Biolase.
Biolase is in the Health Care sector and Health Care Equipment & Supplies industry. They are listed on the NASDAQ.